The protection of hematopoietic stem and progenitor cells and their environment is required for recovery from radiation-induced (RI) myelosuppression. To achieve this goal, we propose a new gene therapy strategy based on local and short-term synthesis and expression of Sonic hedgehog morphogene (Shh) at the niche level. We investigated the hematopoietic response of 8 Gy gammairradiated monkeys to a single intra-osseous injection of multipotent mesenchymal stem cells (adipocyte-derived stem cells/ASC) transduced with a Shh pIRES2 plasmid (3 þ / À 0.4 Â 10 6 cells/kg on day (D) 2; n ¼ 4). Control animals were injected with mock-ASCs (n ¼ 4). Two controls died from radiation toxicity on D19 and D196, whereas all Shh-ASC treated monkeys fully recovered. Thrombocytopenia (4.75 þ / À 1.8 days versus 10 þ / À 2.2 days, platelet count o20 Â 10 9 /L), neutropenia (14.2 þ / À 1 days versus 17.7 þ / À 2.6 days, ANC counto0.5 Â 10 9 /L) and anemia (15.5 þ / À 3.6 days versus 50.7 þ / À 31 days, Hb less than 10 g/dL) duration were reduced in Shh-ASC animals. Areas under the curve of platelets (Po0.05), ANCs (P ¼ 0.06) and RBC/Hb between D0 and D30 were higher in Shh-ASC injected animals. Globally this study suggests that Shh may represent a new factor to counteract RI-myelosuppression.
INTRODUCTION
Following accidental or intentional/terrorist exposure to ionizing radiation, medical management of the hematopoietic syndrome consists of hematopoietic growth factor administration in the case of intermediate BM damage (3 to 7 Gy) and allogeneic hematopoietic stem cell (HSC) transplantation if BM has been severely depleted (47Gy). 1, 2 Optimizing this therapeutic scheme-especially with the aim of raising the transplantation threshold-is required to cope with mass casualty scenarios and complex combined injury syndrome. Revisiting the global hematopoietic tissue response according to the niche hypothesis may represent a promising approach to achieve this goal.
Indeed, many experimental data have shown that HSCs reside within a specialized microenvironment created by supporting cells that express membrane-bound proteins and secreted factors. 3, 4 The stem cell niche represents a fundamental orchestration level of communications between HSC and their environment. This microenvironment regulates HSC maintenance, migration, quiescence and differentiation. BM stromal cells composed of fibroblasts, macrophages, endothelial cells and adipocytes serve as a rich source of growth factors. Indeed, many different cell types contribute to formation of HSC niche near the endosteum and around sinusoids. Osteoblasts, adventitial reticular cells and BM sinusoids are thought to represent critical regulators of hematopoiesis. 5, 6 Endothelial cells and angiocrine factors represent a crucial level of microenvironment organization-the vascular niche-and the capacity of BM endothelial cells to balance the expansion and differentiation of long-term HSC has recently been reported. 7 Importantly, although little is known in terms of intercellular pro-death and survival signals, the HSC environment represents a complex radio-sensitive compartment whose repair/manipulation appears crucial for stem cell survival and recovery from radiationinduced (RI) myelosuppression. Among the different candidates regulating directly/indirectly hematopoiesis the hedgehog signaling pathway, one of the three mammalian hedgehog proteins, represents a major actor in steady state and stress-induced adult hematopoiesis. [8] [9] [10] It has been reported to induce the expansion of human pluripotent hematopoietic repopulating cells in immunocompromized mice via bone morphogenetic protein regulation. 11 In hedgehog responsive cells, binding on Patched1 receptor modifies the expression of bone morphogenetic protein 4 and its inhibitor Noggin the balance of which achieves hematopoietic cell self renewal. However, other studies have challenged this Patched1 mediated myeloid and lymphoid regulation. 12, 13 Regarding the microenvironment it has been reported that Sonic hedgehog morphogene (Shh) may be involved in the vascularization of certain embryonic tissues and stimulation of pro-angiogenic activity in adult. 14, 15 In this study, we hypothesized that Shh may represent a key factor to mitigate RI damage. We tested a short-term gene therapy strategy based on intra-osseous injection of adipocyte-derived stem cells (ASCs) manipulated ex vivo using the nucleofection/ Amaxa technology to secrete Shh. This treatment resulted in an accelerated hematopoietic recovery, an effect that persisted over 1 year.
MATERIALS AND METHODS Animals
Adult male rhesus monkeys (Macaca mulatta) weighing 8.5 þ /0.8 kg (n ¼ 10) were housed at the IRBA accredited facility in individual cages in holding rooms. Biological sample collection and animal management were carried out under general anesthesia with ketamine (Imalgene, Mé rial, Lyon, France; 10 mg/kg i.m.). Animal experiment was approved by the local ethics committee.
Adipocyte-derived stem cells
Pigs were used as an easier model than non human primates to grow MSCs over passages. 16 ASCs were isolated from porcine s.c. adipose tissue under general anesthesia. Fat tissue was minced and incubated for 60 min at 37 1C with collagenase II (Worthington, Lakewood, NJ, USA). After centrifugation, the pelleted cells were seeded in 150 cm 2 
Gene therapy
For the gene therapy study, soluble N-terminus human Shh isoform required for Shh biological activity was cloned in a bicistronic pIRES2-EGFP plasmidic vector (Clonetech Laboratories, Mountain View, CA, USA), which allows the gene of interest and the EGFP reporter gene to be translated separately from a single bicistronic mRNA. Nucleofection was performed using the Nucleofector II and the human MSC Nucleofector Kit (Amaxa Biosystems part of Lonza, Levallois-Perret, France). 17, 18 Briefly 5 mg of plasmid were added to 10 Â 10 6 trypsinized ASCs suspended in human MSC nucleofector solution under a 100-mL volume. After 4 days of incubation in MEMa medium, all viable cells were grafted. The Shh-ASCs subpopulation (EGFP-positive cells) was quantified using flow cytometry (BD LSRII, BD Biosciences). The secretory capacity of grafted cells was controlled in vitro in a short-term ASC culture assay using western blot analysis. Membranes were probed with polyclonal goat anti-human Shh Ab 1/1000 (SantaCruz Biotechnology, Heildelberg, Germany) followed with incubation of anti-IgG conjugated with peroxidase Ab 1/5000 (SantaCruz Biotechnology). Intensity of the band was determined by densitometry (Genegnome, Syngene, Cambridge, UK). Western blot analysis confirmed Shh secretion for about 9 days ( Figure 1 ). Four animals were given at least 2 Â 10 6 Shh-ASCs /kg, which were postulated to represent the therapeutic threshold corresponding to more than 3.8 Â 10 6 /kg total ASCs. As controls, four animals were injected with corresponding amounts of ASCs following nucleofection using a mock-EGFP plasmidic vector.
Injection procedure
Anesthetized monkeys placed in a restraining chair were exposed to a whole body (TBI) unilateral front irradiation with a 60 Co gamma source to a total midline tissue dose of 8 Gy (measured in air at the anterior iliac crest level) with a dose rate X10 cGy/min. Dosimetry was performed using a 0.3 cm 3 ionizing chamber and thermoluminescent alumin dosimeters. Shhand mock-ASCs were injected in a single humerus 2 days after irradiation. Cells were delivered using a pediatric aspiration needle under a 4-ml PBS volume (1 min injection schedule).
Animal care
All monkeys were transfused with fresh whole blood irradiated with a 20-Gy dose ( 137 Cs source) when the platelet count was less than 20 Â 10 9 /L or the hematocrit less than 20% in presence of clinical symptoms (petechia, epistaxis). Ampicillin (50 mg/kg/day) and gentamycin (1.5 mg/kg/day) were provided during neutropenia (ANC o0.5 Â 10 9 /L).
Hematopoietic evaluations
Complete and differential blood cell counts (CBC) were performed on a Pentra 120 analyzer (ABX, Montpellier, France) and using May-Grü nwald stain (Sigma, Saint-Quentin Fallavier, France). Durations of neutropenia, thrombocytopenia, lymphopenia and anemia were defined, respectively, as the times when ANC, platelet and lymphocyte (Ly) counts and Hb were o0.5 or 1 Â 10 9 /L, 20 or 50 Â 10 9 /L, 1 Â 10 9 /L and less than 10 g/dL. Shortand middle-term reconstitution was estimated from the area under the curves (AUC) of the different blood cell counts from day D0 to D30 and D90 post TBI, based on trapezoid area calculation.
BM was aspirated from the humerus and posterior iliac crest before TBI (that is, baseline) and then on D42 and XD180. Low density (1.070 g/cm 3 ) mononuclear cells were separated and cultured for colony-forming unit (CFU) evaluation in either methyl cellulose medium (MethoCult H4435 for CFU-granulocyte-macrophage (CFU-GM), burst-forming erythroid (BFU-E), and CFU-granulocyte-erythrocyte-monocyte-megakaryocyte (CFU-GEMM) or a collagen-based medium for CFU-megakaryocyte (CFU-MK; MegaCult-C; both from Stem Cell technologies, Meylan, France). Colonies were scored on D14 and absolute number of each type of CFU for 1 Â 10 5 mononuclear cells was determined.
Statistical analysis
Results are expressed as means þ / À s.d. and non parametric MannWhitney U-test was used.
The assay data were additionally analyzed by principal component analysis (PCA) using GenEx software (version 5.4, MultiD, Gö teborg, Sweden). PCA is a statistical visualization method for multivariable data sets, which reduces the dimensionality while exposing the maximal variation embedded. 19 PCA involves a mathematical procedure that transforms a number of variables (here AUCs) into a smaller number of uncorrelated variables called principal components (here visualized on PC1-3 axis) and measured by the eigen value. The first principal component (PC1) contains the greatest fraction of the overall variance of the data. 
RESULTS

Hematopoietic recovery of mock-ASC injected animals
Mock-ASC grafted animals were given 4.4 þ / À 0.9 cells/kg (Table 1) . One monkey died from BM aplasia on D19 in spite of supportive care and another one from extra-hematological toxicity (cachexia and lung disease) on D196. Animals exhibited a period of profound pancytopenia as shown in Table 2 . Duration of neutropenia (ANC less than 0.5 Â 10 9 /L), thrombocytopenia (platelets less than 20 Â 10 9 /L), lymphopenia and anemia in animals surviving the hematopoietic syndrome were 17.7 þ / À 2.6 days, 10 þ / À 2.2 days, 29.7 þ / À 3 days and 50.7 þ / À 31 days, respectively ( Table 2, Figures 2a-c) . On D42, the frequency of total CFU-GMs and total CFU-MKs partially recovered, whereas CFUGEMMs and BFU-Es were normalized (Table 3) . These changes persisted for over 180 days in the two surviving animals. D30 and D90 AUCs for platelets, ANCs, RBCs and Hb did not differ from two historic animals injected with PBS (Table 4) .
Influence of Shh-ASC grafting on hematopoietic recovery Varying numbers of Shh-ASC were injected (range 2.05-3.74 Â 10 6 Shh-ASCs/kg; Table 1 ). All animals survived and no relationship between the Shh-ASC content and hematopoietic parameters was observed. The duration of neutropenia (ANC less than 0.5 Â 10 9 /L) was moderately reduced (14.2 þ / À 1 days) with a notable overshoot between day 25 and day 40 (Table 2, Figure 2a ). From about month 2, ANCs remained stable at the baseline level. The animals exhibited a very short period of thrombocytopenia (4.75 þ / À 1.8 days for platelet less than 20 Â 10 9 /L) and platelet count strongly increased up to about D40 (Figure 2b ). The duration of anemia was shortened (15.5 þ / À 3.6 days) and no grafted animal exhibited epistaxis; blood transfusion needs were reduced (Table 2, Figure 2c ). On D42 humeral, and posteror iliac crest and CFU-GMs and CFU-MKs activities were increased when compared with those observed in mock-ASC counterparts (Table 3 ). Globally no difference was observed between injected and uninjected humerus (data not shown). Similarly D30 AUCs for platelets (Po0.05), ANCs (P ¼ 0.06), RBCs and Hb were increased in Shh-ASC engrafted monkeys (Table 4) . D90 AUCs for platelets Table 2 . Blood Hematologic Parameters of rhesus monkeys unilaterally irradiated at 8 Gy with 60 Co gamma radiation
Duration of thrombocytopenia, platelet o20 Â 10 (Table 4) . To validate our observations we used PCA. Figure 3 shows the first three principal components fitted to the Shh and mock AUCs profile data. The first components discriminate Shh and mock monkeys (eigen value of 99.6%). Most of encounted variation was due to D30 platelet AUC, D90 platelet AUC and D90 Hb AUC. Figure 3 shows that three out of four treated animals responded more strongly to the treatment that the latter one. Finally, no delayed impairment of hematopoiesis was observed between D180 to D360 (data not shown).
DISCUSSION
The results of this study in highly irradiated monkeys (8 Gy gamma TBI) demonstrate that Shh may be potentially therapeutic. Interestingly, the early (D2) intra-osseous injection of Shh-ASCs as a single treatment stimulated multilineage hematopoietic recovery in myelosuppressed animals.
Hematopoietic stem and progenitor cells are known to be radiosensitive. Their direct exposure to ionizing radiation at a dose of 2.5 Gy in vitro leads to a wave of apoptosis and necrosis within 24 h of exposure. 20 In addition, RI microenvironment damage may Here, we hypothesized that Shh represents a pleiotropic therapeutic factor that prevents or reduces myelosuppression. As morphogenes are major actors of oncogenic processes, we conceived a short-term in situ delivery system using ASCs as vectors following in vitro transduction. In vitro we confirmed that transduced ACSs synthetized and secreted Shh in the culture milieu during about 10 days. At this time the Shh cell content decreased indicating protein synthesis stopping. In vivo the high radiation dose chosen accounted for the death of two animals in the mock-ASC group (one early and one delayed from cardiopulmonary toxicity), whereas all Shh-ASC monkeys survived. ASCs treated animals experienced an accelerated multilineage recovery with a dramatic ANC overshoot and an acceleration of platelet recovery, albeit the limited size of the Shh-ASC group and the death ratio in controls limited statistical significance. PCA analysis clearly discriminates Shh and mock groups. This is likely to be mainly related to a stimulatory effect on residual hematopoietic stem and progenitor cells. A pro-survival effect was not expected as the main part of cell necrosis and apoptosis processes have already occurred at D2-the time chosen for Shh-ASCs injection to mimic accidental logistic constraints. In fact CFU-GM and CFU-MK activities were impaired at D42 in both groups, albeit to a lesser extent in Shh-ASC animals. At this time, ANC and platelet counts have reached a plateau suggesting the interest of an earlier evaluation. Anemia period was reduced in accordance with Harandi et al. 26 who proposed bone morphogenetic protein 4 manipulation as a new therapeutic approach to favor the emergence of self renewing population of stress erythroid progenitors. CFU-GEMM and BFU-E normalized in both groups at this time corresponding to a dramatic RBCs increase-with a notable delay for controls. Globally these results are compatible with our transient stimulatory pulse hypothesis. Within the Shh-ASC injected group, the hematopoietic response indicated that the efficacy cell threshold has been exceeded and D360 hematopoiesis was not compromised. Protective effect on microenvironment may also have occurred. We acknowledge that regarding the morphogene target(s), we did not provide definitive arguments and that further experiments are required. Interestingly, Shh-ASCs matrigel grafted in immunocompromized mice exhibited an increase in RBC colonization when compared with mock-ASCs counterparts (data not shown). Whether ASCs or preserved/stimulated hematopoietic progenitors may have migrated after cell drug intra-osseous injection in monkeys remains to be established as well as Shh and cytokines related putative release in the venous system. Few non hematopoietic cell/gene therapy approaches have been yet proposed to mitigate RI-myelosuppression. Interestingly, Chute's group has established the capacity of specific primary murine brain-derived endothelial cells to promote the repair of 4 Gy in vitro irradiated HSCs and to improve the hematopoietic recovery and survival of irradiated mice. 27 According to the authors, this effect was related to soluble factor release and did not involve BM engraftment. Here, using a xenogeneic model of pig ASCs injected to monkeys, the present study suggests that Shh transient gene therapy may represent a new innovative strategy to favor hematopoietic recovery. 
